Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis

Lancet. 2003 May 3;361(9368):1521-3. doi: 10.1016/s0140-6736(03)13171-6.


An increase in invasive Hib disease incidence in the UK has coincided with the distribution of combination vaccines that contain acellular pertussis (DTaP-Hib). These vaccines have been associated with reduced immunogenicity of the Hib component, although there is little agreement on the clinical relevance of this finding. We retrospectively compared vaccine formulations given to fully vaccinated Hib cases with those administered to fully immunised age-matched controls using conditional logistic regression. More cases than controls received all three doses of their infant primary course as DTaP-Hib, compared with two or three doses of another Hib vaccine (conditional odds ratio 6.77 [95% CI 3.26-14.07]).

MeSH terms

  • Diphtheria-Tetanus-Pertussis Vaccine / standards*
  • Haemophilus Vaccines / standards*
  • Haemophilus influenzae type b*
  • Hepatitis B Vaccines / standards*
  • Humans
  • Immunization Schedule
  • Incidence
  • Infant
  • Meningitis, Haemophilus / epidemiology*
  • Meningitis, Haemophilus / prevention & control
  • Regression Analysis
  • Retrospective Studies
  • Risk Factors
  • Treatment Failure
  • United Kingdom / epidemiology


  • Diphtheria-Tetanus-Pertussis Vaccine
  • Haemophilus Vaccines
  • Hepatitis B Vaccines
  • diphtheria-tetanus-acellular pertussis-Hib-hepatitis B vaccine